Research Paper Volume 12, Issue 20 pp 20835—20861

SMARCD3 is a potential prognostic marker and therapeutic target in CAFs

Figure 4. SMARCD3, CRIP2, PRAM1, HSPB2 and CERCAM could activate EMT in multiple cancer types (upper panel), while SMARCD3, CRIP2, PRAM1 and HSPB2 are associated with cell cycle inhibition (lower panel).